Natera, Inc. $NTRA Shares Purchased by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership boosted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 47.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 37,454 shares of the medical research company’s stock after buying an additional 12,085 shares during the period. Artisan Partners Limited Partnership’s holdings in Natera were worth $6,029,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Sound Income Strategies LLC raised its holdings in shares of Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after acquiring an additional 110 shares during the period. Quent Capital LLC acquired a new stake in Natera during the third quarter worth about $46,000. Hilltop National Bank raised its stake in Natera by 59.8% during the third quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock worth $50,000 after purchasing an additional 116 shares during the period. N.E.W. Advisory Services LLC boosted its holdings in Natera by 256.8% in the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 226 shares during the last quarter. Finally, AXS Investments LLC purchased a new stake in shares of Natera in the 3rd quarter valued at approximately $69,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Natera news, Director Herm Rosenman sold 48,419 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $227.42, for a total value of $11,011,448.98. Following the completion of the transaction, the director owned 20,342 shares of the company’s stock, valued at $4,626,177.64. This trade represents a 70.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Michael Burkes Brophy sold 37,175 shares of the business’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50. Following the completion of the transaction, the chief financial officer owned 64,123 shares of the company’s stock, valued at approximately $15,552,392.42. This trade represents a 36.70% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 368,119 shares of company stock valued at $85,956,782. 5.63% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. UBS Group lifted their price target on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Piper Sandler lifted their target price on Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Wells Fargo & Company upped their price target on Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a research note on Friday. Finally, Morgan Stanley increased their price target on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $254.47.

Natera Trading Down 3.7%

NTRA stock opened at $208.04 on Friday. The company has a market capitalization of $28.78 billion, a PE ratio of -135.97 and a beta of 1.64. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36. The business’s fifty day moving average price is $226.52 and its 200 day moving average price is $203.85.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative return on equity of 16.71% and a negative net margin of 9.03%.During the same period last year, the business posted ($0.41) EPS. Research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Quarterly beat — Natera reported Q4 revenue of $665.5M and GAAP EPS of $0.35, well ahead of street estimates (revenue ~$600.7M, EPS loss consensus). The beat supports near-term growth expectations and underpins the stock’s recent strength. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Favorable clinical data — New Signatera MRD data presented at ASCO GU highlight potential utility across genitourinary cancers (including bladder preservation), which may expand clinical adoption and long-term revenue for Natera’s oncology franchise. Signatera MRD Data at ASCO GU
• Positive Sentiment: Trial results — Natera reported results from the SINERGY trial, another clinical datapoint that could support commercial adoption of its assays. Natera Announces Results From the SINERGY Trial
• Positive Sentiment: Analyst upgrades/targets — Robert W. Baird raised its price target to $257 (outperform) and Wells Fargo raised its target to $215 (equal weight), signaling some sell-side confidence in upside from current levels. Benzinga – Analyst Price Target Changes
• Neutral Sentiment: Full-year revenue guidance roughly in line with consensus — Management issued FY2026 revenue guidance (roughly $2.6B–$2.7B), which appears consistent with street expectations and reduces upside surprise potential from guidance alone. (See Q4 release for guidance details.) Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst consensus — Aggregated analyst coverage remains constructive (average “Moderate Buy”), which supports medium-term expectations but doesn’t preclude short-term volatility. Analyst Average Rating
• Negative Sentiment: Valuation and fundamentals concerns — Despite the beat, Natera still shows negative net margin and negative return on equity on a GAAP basis; combined with a high market capitalization and a recent run-up toward 52-week highs, investors may be taking profits. MarketBeat Q4 Coverage
• Negative Sentiment: Heavy intraday volume and selling pressure — Trading volume was well above average, consistent with a distribution day where some holders trimmed positions after the company’s strong quarter; that drove the stock lower despite the positives. (See intraday volume and price action for context.)

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.